Rinvask Drug Interactions

Cyclosporine: Cyclosporine may increase pitavastatin concentrations. Coadministration of cyclosporine with pitavastatin is contraindicated (see Contraindications).
Erythromycin: Erythromycin may increase pitavastatin concentrations. In patients taking erythromycin, the pitavastatin dose should not exceed 1 mg once daily (see Dosage & Administration).
Rifampicin: Rifampin may increase pitavastatin concentrations. In patients taking rifampicin, the pitavastatin dose should not exceed than 2 mg once daily (see Dosage & Administration).
Gemfibrozil: Because of the increased risk of myopathy/rhabdomyolysis when co-administered with HMG-CoA reductase inhibitors, concomitant administration of pitavastatin with gemfibrozil should be avoided.
Other Fibrates: As the risk of myopathy may be increased when coadministered with HMG-CoA reductase inhibitors and fibrates, pitavastatin should be administered with caution when coadministered with fibrates (see Precautions).
Niacin: Muscle pain may increase when pitavastatin is coadministered with niacin; a pitavastatin dose reduction should be considered (see Precautions).
Warfarin: Pitavastatin has no pharmacokinetic interactions with R- and S-warfarin. Pitavastatin does not affect prothrombin time (PT) or international normalized ratio (INR) when administered to patients receiving chronic warfarin therapy. Patients receiving warfarin should have their prothrombin time (PT) and international normalized ratio (INR) monitored when co-administered with pitavastatin.
Pediatric population: No data available in the pediatric population.